Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | PPID | Q08752 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CFD | P00746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714625 | 0.84 | EPHX1 (0.77) | SMN1; SMN2EPHX1PTPN1EPHX2PPID | |
| SCHEMBL7749740 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2EPHX1PTPN1EPHX2PPID | |
| SCHEMBL2085393 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2EPHX1PTPN1EPHX2PPID | |
| SCHEMBL970225 | 0.79 | SMN1; SMN2 (0.70) | SMN1; SMN2EPHX1PTPN1EPHX2PPID | |
| SCHEMBL13049648 | 0.78 | SMN1; SMN2 (1.00) | SMN1; SMN2EPHX1PTPN1EPHX2PPID | |
| SCHEMBL27942162 | 0.77 | NPC1 (0.83) | SMN1; SMN2EPHX1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL969258 | 0.77 | SMN1; SMN2 (0.67) | SMN1; SMN2EPHX1PTPN1EPHX2PPID | |
| SCHEMBL6033584 | 0.77 | TP53 (0.75) | SMN1; SMN2EPHX1PTPN1EPHX2TP53 | |
| SCHEMBL15272208 | 0.76 | MEN1 (0.55) | EPHX2LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL1134902 | 0.76 | EPHX1 (0.71) | SMN1; SMN2EPHX1PTPN1EPHX2PPID |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| WO-2014205414-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-12-24 | — | — | WO | disclosed |
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-1873159-A1 | Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1873159-A1 | Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007147575-A2 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISINGS SAME, METHODS OF PREPARING SAME AND USES SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | NQO1, TXN2, MPO | SMN1; SMN2 1033/4885EPHX1 3535/4885PTPN1 1974/4885 |
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | TIE1, KDR, TEK | SMN1; SMN2 764/4885EPHX1 2930/4885PTPN1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.